Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2021-11-16 Report Publication Anno…
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2021
Report Publication Announcement Classification · 100% confidence The document is titled "Preliminary announcement of the publication of quarterly reports and quarterly/interim statements." It explicitly states that it is announcing *when* and *where* future financial reports (Q1 and Q3 reports) will be disclosed, providing dates and links for future disclosure. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports, rather than being the report itself (like an IR or ER). The document length is short (2196 chars), further supporting the RPA classification over a comprehensive report.
2021-11-16 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding transactions (Disposal) made by a 'person discharging managerial responsibilities' (Dr. Francesco De Meo, Member of the managing body) in the company's shares. This directly matches the definition for Director's Dealing reports.
2021-11-11 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'DGAP-DD: Fresenius SE & Co. KGaA english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This content directly corresponds to the definition of Director's Dealing reports, which are classified under the code DIRS. The document details transactions (exercise of options and sale of shares) by a member of the managing body (Stephan Sturm) on a specific date (2021-11-04).
2021-11-05 English
Q3 statement / Q3 financial report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Financial Report' for Q3 2021, containing detailed financial statements (income statement, balance sheet, cash flow), segment reporting, and management discussion and analysis. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-04 German
Conference Call Q3 Results 2021, Fresenius
Investor Presentation Classification · 99% confidence The document text explicitly states "Conference Call | Q3/21 Results" and provides an agenda, key messages, segment performance breakdowns (Fresenius Kabi, Helios, Vamed) for Q3/21 and Q1-3/21, P&L statements, cash flow tables, and forward-looking outlooks. This structure, focusing on discussing recent quarterly results in a presentation format, is characteristic of an earnings call presentation, which is transcribed or presented during a conference call. Therefore, the most appropriate classification is Call Transcript (CT), as the content is clearly derived from or is the presentation used during such a call.
2021-11-02 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights' and details a 'Type of capital measure' (Conditional capital increase). This directly relates to changes in the total number of shares that carry voting rights, which is a specific corporate action announcement. This fits best under the category related to voting rights or capital structure changes. Since it is an announcement about the total voting rights count, it is most closely aligned with Declaration of Voting Results & Voting Rights Announcements (DVA), although it is not the *result* of a vote, but the *basis* for voting rights. Given the options, DVA is the most specific fit for an announcement concerning the total voting rights count, which is fundamental to shareholder voting power. It is not a general regulatory filing (RNS) because DVA is more specific. It is not a capital change (CAP) because it is specifically about the *voting rights* count resulting from a capital measure, not the financing itself.
2021-10-29 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.